New Data Show Growing Complexity of Drug Overdose Deaths in America

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email
In-depth analysis confirms sharp increases, geographic spread of synthetic opioid-related deaths

Centers for Disease Control and Prevention Press Release
For Immediate Release: Friday, December 21, 2018
Contact: Media Relations
(404) 639-3286

U.S. overdose death rates linked to synthetic opioids, likely from illicitly manufactured fentanyl (IMF), increased more than 45 percent from 2016 to 2017 while death rates from heroin and prescription opioids – still far too high – remained stable.

The findings come from an in-depth CDC analysis of the latest available drug overdose death data and expands upon data released in November by the National Center for Health Statistics. The report, published online today in an early release from CDC’s MMWR, analyzes the growing number of U.S. drug overdose deaths from 2013 to 2017, and by demographic and geographic characteristics from 2016 to 2017. More than 702,000 Americans have died from drug overdoses from 1999 to 2017 – about 10 percent of them in 2017 alone.

“The drug overdose epidemic continues to evolve, with the involvement of many types of drugs including opioids, cocaine, and psychostimulants,” said Debra Houry, M.D., M.P.H., director of CDC’s National Center for Injury Prevention and Control. “This underscores the urgency for more timely and localized data to inform public health and public safety action.”

Synthetic opioid deaths expanded in 2017

Opioids were involved in over two-thirds of overdose deaths in 2017. Of the 35 jurisdictions reporting data sufficient for analysis, 23 states and the District of Columbia saw increased rates of death linked to synthetic opioids. IMF likely drove the 1.5-fold increase in deaths involving synthetic opioids from 2016 to 2017.

Previously, deaths involving synthetic opioids mainly occurred east of the Mississippi River. The latest available data now show eight states west of the Mississippi had significant increases in such deaths: Arizona, California, Colorado, Minnesota, Missouri, Oregon, Texas, and Washington.

While overdose deaths involving synthetic opioids expanded, heroin- and prescription-opioid-involved deaths remained stable from 2016 to 2017. However, overdose death rates involving heroin and prescription opioids were, respectively, seven and four times higher in 2017 than in 1999.

Some preliminary indicators in 2018 point to possible improvements based on provisional data; confirmation will depend on final 2018 data and results of pending medical investigations.

The drug overdose epidemic grew and evolved in 2017

There were more than 70,000 drug overdose deaths in 2017, with a rate of 21.7 per 100,000 population. The rate increased by nearly 10 percent from 2016.

The rates of overdose deaths involving cocaine increased by more than 34 percent. The rate of overdose deaths involving psychostimulants increased by more than 33 percent.

Opioid death rates differed across the states examined in this study, with the highest relative increases occurring in North Carolina, Ohio, and Maine. From 2016 to 2017, opioid-involved deaths:

• Increased for both sexes.
• Increased among all people in all age groups over the age of 25.
• Increased among white, black, and Hispanic people.
• Had the largest absolute death rate increase in males 25-44.
• The largest percent change increases in opioid-involved death rates were among blacks (25.2 percent) and adults over age 65 (17.2 percent).

What is being done?

A whole of government approach is being led by the U.S. Department of Health and Human Services (HHS) to prevent and respond to drug overdoses, specifically those involving opioids. The HHS five-point strategy provides: better treatment, better data, better research, increased access to naloxone, and better pain management. Within HHS, CDC conducts surveillance and research; builds state, local, and tribal capacity for prevention; supports providers, health systems, and payers; partners with public safety; and empowers consumers to make safe choices.

“Drug overdose and opioid-involved deaths are a critical public health issue. It is important for CDC to share these data so states and communities have the information needed to inform their prevention activities and better respond,” said the report’s lead author and epidemiologist Lawrence Scholl, Ph.D., National Center for Injury Prevention and Control.

CDC is working with states across the country through the Enhanced State Opioid Overdose Surveillance (ESOOS) program to develop a multifaceted approach for faster and more comprehensive surveillance to track emerging threats in order to prevent and respond to the epidemic.

Today’s report also reinforces the continued need for response strategies including increasing naloxone availability, educating patients and providers about safe prescribing practices, reducing the syndemic of infectious diseases and opioid overdoses, providing patients with linkage into treatment, and fostering greater collaboration between public health and public safety.

Full Press Release

More To Explore

What is The Rx Consultant?

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. All our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

For 30 years The Rx Consultant has operated independent of the pharmaceutical industry and has no commercial bias.

Join thousands of healthcare providers who enjoy the following benefits every month.

1. Drug Therapy Updates & Reviews

The eLibrary contains over 30 streamlined updates on drug therapy for the most common diseases. New articles are added every month – it is a continually expanding resource.

2. Continuing Education

The eLibrary includes 50+ hours of Pharmacology CE from an ACPE approved provider at no additional charge. Each article provides at least 1.5 hours of Pharmacology CE. Subscribers can take their tests online, score them immediately, then print or save their credit statements. Pharmacology CE tests can also be mailed, faxed, or even phoned in to The Rx Consultant office, and credit statements will be delivered by mail or fax.

3. Unlimited Access to our Resource Library, with:

  • Healthcare News

    The eLibrary includes a news column covering the developments that matter most to nurse practitioners and other front-line providers. You get a headline, the bottom line, and how it’s likely to affect your practice in a few short lines, then it’s on to the next news item. The news briefs are also available in print monthly as Rx News Connection.
  • Patient Education Pages

    Patient Q&A to sharpen your skills in educating patients and answering common questions.
  • Charts & Tables

    At-a-glance updates on drugs, doses, common side effects & interactions
  • Quick Facts

    Key facts organized for fast access both online and on handy reference cards.
  • The Bottom Line

    Our members suggest the topics and each issue undergoes a rigorous three month peer reviewed process. Our CE is different because we accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.

The Rx Consultant maintains a high standard for quality

And a rigorous system for content development that insures it. Every issue is written by an expert in the topic area, and then peer reviewed, fact-checked and edited to insure that the content is

  • Evidence-based
  • Non-Biased
  • Balanced
  • Timely
  • Accurate and
  • Useful for community practitioners

The Rx Consultant is completely independent of the pharmaceutical industry.

We accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.